{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2","upperLimit":"11.6","value":"6.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"}],"units":"Participants"}],"description":"Time to treatment failure is defined to be the time from registration to the date at which the patient is removed from treatment due to progression, adverse events, or refusal. If the patient is considered to be a major treatment violation or is taken off study as a non-protocol failure, the patient will be censored on the date they are removed from treatment. The distribution of time to treatment failure will be estimated using the method of Kaplan-Meier.","dispersionType":"95% Confidence Interval","groups":[{"description":"Rituximab 375 mg/m2 IV on day 1\n\n\\> Cyclophosphamide 300 mg/m2 PO on days 1, 8, 15, 22\n\n\\> Bortezomib 1.3 mg/m2 IV on days 1, 8, 15, 22\n\n\\> Dexamethasone 40 mg PO on days 1, 8, 15, 22","id":"OG000","title":"Treatment"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Up to 3 years from registration","title":"Time to Treatment Failure","type":"SECONDARY","unitOfMeasure":"months"}